Literature DB >> 19111801

Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy?

Eric A Klein1, Jay Ciezki, Patrick A Kupelian, Arul Mahadevan.   

Abstract

The treatment of localized prostate cancer remains controversial because of the lack of conclusive well-controlled or randomized studies comparing outcome of various forms of radiotherapy (RT) to radical prostatectomy (RP). We review recent results from an institutional database and prospective quality of life study comparing cancer-related and quality of live (QOL) outcomes among different treatment modalities for intermediate risk prostate cancer. The results suggest similar short-term survival but domain-specific effects on QOL after treatment with radical prostatectomy, brachytherapy, or external beam radiotherapy.

Entities:  

Mesh:

Year:  2009        PMID: 19111801     DOI: 10.1016/j.urolonc.2008.04.001

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  26 in total

1.  A hormone-DNA repair circuit governs the response to genotoxic insult.

Authors:  Jonathan F Goodwin; Matthew J Schiewer; Jeffry L Dean; Randy S Schrecengost; Renée de Leeuw; Sumin Han; Teng Ma; Robert B Den; Adam P Dicker; Felix Y Feng; Karen E Knudsen
Journal:  Cancer Discov       Date:  2013-09-11       Impact factor: 39.397

2.  Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer.

Authors:  George Rodrigues; Xiaomei Yao; D Andrew Loblaw; Michael Brundage; Joseph L Chin
Journal:  Can Urol Assoc J       Date:  2013 May-Jun       Impact factor: 1.862

3.  Identification of a clinically relevant androgen-dependent gene signature in prostate cancer.

Authors:  Hannelore V Heemers; Lucy J Schmidt; Zhifu Sun; Kevin M Regan; S Keith Anderson; Kelly Duncan; Dan Wang; Song Liu; Karla V Ballman; Donald J Tindall
Journal:  Cancer Res       Date:  2011-02-15       Impact factor: 12.701

4.  Differences in practice patterns between urologists and radiation oncologists in the management of localized prostate cancer: a cross-sectional survey.

Authors:  Mehdi Mokhtar Ariane; Guillaume Ploussard; Xavier Rebillard; Bernard Malavaud; Pascal Rischmann; Christophe Hennequin; Pierre Mongiat-Artus
Journal:  World J Urol       Date:  2015-03-31       Impact factor: 4.226

Review 5.  Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer: A systematic review.

Authors:  George Rodrigues; Xiaomei Yao; D Andrew Loblaw; Michael Brundage; Joseph L Chin
Journal:  Can Urol Assoc J       Date:  2013-11       Impact factor: 1.862

6.  PEG spacer gel and adaptive planning vs single plan in external prostate radiotherapy--clinical dosimetry evaluation.

Authors:  Vesa-Pekka Heikkilä
Journal:  Br J Radiol       Date:  2015-09-15       Impact factor: 3.039

7.  Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer.

Authors:  Michael J Zelefsky; Yoshiya Yamada; Xin Pei; Margie Hunt; Gilad Cohen; Zhigang Zhang; Marco Zaider
Journal:  Urology       Date:  2010-12-31       Impact factor: 2.649

8.  RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.

Authors:  Lucy J Schmidt; Kelly Duncan; Neelu Yadav; Kevin M Regan; Alissa R Verone; Christine M Lohse; Elena A Pop; Kristopher Attwood; Gregory Wilding; James L Mohler; Thomas J Sebo; Donald J Tindall; Hannelore V Heemers
Journal:  Mol Endocrinol       Date:  2012-03-28

Review 9.  AR function in promoting metastatic prostate cancer.

Authors:  Michael A Augello; Robert B Den; Karen E Knudsen
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

Review 10.  Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.

Authors:  Karen E Knudsen; Howard I Scher
Journal:  Clin Cancer Res       Date:  2009-07-28       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.